scholarly journals Low tumor necrosis factor-α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder

2018 ◽  
Vol 8 (4) ◽  
pp. e00933 ◽  
Author(s):  
Annamari Sorri ◽  
Kaija Järventausta ◽  
Olli Kampman ◽  
Kai Lehtimäki ◽  
Minna Björkqvist ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Tumor Necrosis Factor ◽  
Depressive Disorder ◽  
Electroconvulsive Therapy ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Symptom Reduction ◽  
Major Depressive ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Increased soluble tumor necrosis factor-α receptors in patients with major depressive disorder

2009 ◽  
Vol 63 (2) ◽  
pp. 202-208 ◽  
Author(s):  
Rodrigo Grassi-Oliveira ◽  
Elisa Brietzke ◽  
Júlio C. Pezzi ◽  
Rodrigo P. Lopes ◽  
Antonio L. Teixeira ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Tumor Necrosis Factor ◽  
Depressive Disorder ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Major Depressive ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Tumor Necrosis Factor-α Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

2020 ◽  
Vol 11 ◽  
Author(s):  
Lin Yao ◽  
LiHong Pan ◽  
Min Qian ◽  
Wei Sun ◽  
ChunHong Gu ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Tumor Necrosis Factor ◽  
Depressive Disorder ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Antidepressant Treatment ◽  
Major Depressive ◽  
Tnf Α ◽  
Factor Α ◽  
Necrosis Factor

Tumor necrosis factor-α (TNF-α) had been identified as a key pro-inflammatory cytokine in the pathophysiology of major depressive disorder (MDD) and the mechanism of antidepressant treatment. The primary aim of the present study was to examine the serum TNF-α levels in Chinese inpatients with MDD during the acute phase and to explore the changes in TNF-α levels after effective clinical treatment. Fifty-seven consecutive inpatients with MDD and 30 healthy controls were recruited. The serum TNF-α levels were detected using ELISA. Symptoms of depression were evaluated using the 24-item Hamilton Rating Scale for Depression (HAM-D-24). TNF-α levels and HAM-D-24 scores were assessed at baseline and after 2 and 12 weeks of follow-up. The serum TNF-α levels were higher in the MDD group than in the control group. After 2 and 12 weeks of antidepressant treatment, there were significant improvements in the patients' symptoms and significant decreases in the TNF-α levels. The baseline TNF-α levels significantly correlated with the decreased HAM-D-24 scores, particularly for the depressive symptoms of anxiety/somatization and weight loss. The present findings indicate that depression is accompanied by activation of TNF-α, which also has a predictive value for the antidepressant treatment response in patients with MDD.

Associations of Tumor Necrosis Factor–α G-308A (rs1800629) Gene Polymorphisms with Major Depressive Disorder

2021 ◽  
Vol 19 (7) ◽  
pp. 133-136
Author(s):  
Aamal Muhsen Kadhum ◽  
Bayader M. Abd Al–Kadim ◽  
Thanaa Chasib Kareem ◽  
Ali Ahmed Nayyef ◽  
Mona N. Al-Terehi
Keyword(s):  
Major Depressive Disorder ◽  
Tumor Necrosis Factor ◽  
Depressive Disorder ◽  
Gene Polymorphisms ◽  
Tumor Necrosis ◽  
Control Group ◽  
Major Depressive ◽  
Allele Distribution ◽  
Tnf Α ◽  
Necrosis Factor

Pro-inflammatory cytokine polymorphisms like Tumor Necrosis Factor- (TNF), has been found associated to severe depressive disorder (MDD). The Pro-inflammatory cytokines tumor necrosis factor (TNF-α) G-308A (rs1800629) have been discovered to have an important role in the pathophysiology of depressive disorders and the mechanism of antidepressant treatment. The present study aims to study TNF-α gene polymorphisms in Major depressive disorder using allele specific PCR. The results show that family history are non- significant different between patients and control group (0.6346) and also there was non- significant different in BMI (0.3417), The genotyping data show tow alleles and three genotyping (AG, GG, AA) the statically analysis show non-significant differences between patients and controls groups (0.095, 0.800) for GG, AA and GA respectively with more frequent of GA in patients than control group, the G allele was less frequent in patient than control while A allele was more frequent in patients than control group in significant differences (0.0001). It can be concluded that TNF genotyping didn’t impact in the Major depressive disorder but the allele distribution may have potential role in MDD patients.

Sign in / Sign up

Export Citation Format

Share Document